Moderna/NIH Trial Coronavirus Vaccine
Moderna, based in Cambridge MA, has started trials of its coronavirus vaccine. In collaboration with the U.S. National Institutes of Health (NIH), the vaccine was developed in just two months after the selection of the genetic sequences to use. The Phase 1 study, which will provide safety and immunogenicity data of the vaccine, will take several months to complete. Moderna has 188 patents and publications, with 3 applications directed to vaccine platforms.
Related Posts
Wellstat Tries to Make Vaccine Eligibility Checks a Reality, but It’s Too Little, Too Late
Imagine spending years developing a way to log patients’ vaccination statuses to develop vaccination plans and not managing to market…
The Pandemic Pivot: a Sign of Ingenuity or Trouble?
The Ideal Industries’ acquisition of Cree Lighting appears to be failing. It may be time to ask: is its pandemic pivot a good or bad…
Dressed to Kill. Viruses that is.
Worried about germs? Instead of spraying everything with sterilizing fluid, what if your clothing got rid of germs by itself? This week,…